Business
Patients in the US undergo first doses of GE HealthCare’s new PET radiotracer, Flyrcado (flurpiridaz F 18) injection
The first patient doses of GE HealthCare’s new FDA-approved PET radiotracer, Flyrcado™ (flurpiridaz F 18) injection, are being administered at early adopter
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nThe first patient doses of GE HealthCare’s new FDA-approved PET radiotracer, Flyrcado™ (flurpiridaz F 18) injection, are being administered at early adopter sites around the United States.\n\n\n\nFirst-of-its-kind radiopharmaceutical, Flyrcado, a PET myocardial perfusion imaging (MPI) agent, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, the predominant procedure used in nuclear cardiology today.\n\n\n\nAvailable as a ready-to-use unit dose, Flyrcado can expand clinician and patient access to PET MPI and is expected to be available to nearly all of the existing cardiac PET centers in the US by the end of 2025.\n\n\n\nGE HealthCare has filed its pass-through application for Flyrcado with the US Centers for Medicaid and Medicare (CMS) to secure procedural codes and reimbursement rates which will further enhance access to the tracer.\n\n\n\n ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--\nGE HealthCare (Nasdaq: GEHC) has delivered the first patient doses of Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent for the detection of coronary artery disease (CAD), at early adopter imaging centers in the US. This milestone follows the recent FDA approval of Flyrcado, which is indicated for patients with known or suspected CAD, and delivers higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) MPI, the predominant procedure used in nuclear cardiology today.\n\n\nDr. Mouaz Al-Mallah, MD, MSc, MASNC, Director of Cardiac PET at Houston Methodist Hospital, said, “Flyrcado opens new frontiers for cardiac PET with a significantly longer half-life than existing PET MPI tracers, and we are proud to be one of the first to use it in our cardiac PET lab. The longer half-life eliminates the need for onsite tracer manufacturing so it can be ordered as a ready-to-use unit dose. Additionally, it offers clinicians the flexibility to perform exercise stress testing—something not feasible with any previously available cardiac PET tracer. We anticipate Flyrcado will make PET MPI more accessible to clinicians and patients and allow more centers to provide this important imaging modality to appropriate patients.”\n\n\nThis month, Houston Methodist Hospital...